Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENLV |
---|---|---|
09:32 ET | 100 | 1.41 |
09:38 ET | 300 | 1.465 |
09:41 ET | 300 | 1.465 |
10:06 ET | 730 | 1.45 |
10:08 ET | 549 | 1.45 |
10:21 ET | 100 | 1.4501 |
11:06 ET | 100 | 1.455 |
11:18 ET | 307 | 1.46 |
11:22 ET | 300 | 1.4501 |
11:49 ET | 1500 | 1.446 |
11:54 ET | 746 | 1.46 |
12:02 ET | 6000 | 1.465 |
12:12 ET | 149 | 1.4639 |
12:21 ET | 200 | 1.465 |
12:27 ET | 500 | 1.4601 |
12:30 ET | 227 | 1.4602 |
12:52 ET | 3303 | 1.48 |
12:56 ET | 400 | 1.475 |
12:57 ET | 1222 | 1.49 |
01:37 ET | 2166 | 1.44 |
01:39 ET | 200 | 1.44 |
01:55 ET | 100 | 1.46 |
01:57 ET | 100 | 1.48 |
02:02 ET | 300 | 1.48 |
02:15 ET | 902 | 1.445 |
02:22 ET | 600 | 1.51 |
02:24 ET | 100 | 1.52 |
02:33 ET | 661 | 1.52 |
02:42 ET | 174 | 1.5005 |
02:47 ET | 1000 | 1.51 |
02:49 ET | 289 | 1.52 |
03:14 ET | 1453 | 1.5 |
03:18 ET | 3788 | 1.45 |
03:20 ET | 133 | 1.481 |
03:21 ET | 200 | 1.48 |
03:38 ET | 1304 | 1.48 |
03:39 ET | 288 | 1.485 |
03:41 ET | 959 | 1.48 |
03:43 ET | 100 | 1.465 |
03:48 ET | 2300 | 1.47 |
03:50 ET | 7704 | 1.435 |
03:57 ET | 1797 | 1.445 |
03:59 ET | 400 | 1.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enlivex Therapeutics Ltd | 28.7M | -0.9x | --- |
Cocrystal Pharma Inc | 28.5M | -1.4x | --- |
NanoViricides Inc | 28.9M | -2.3x | --- |
Lisata Therapeutics Inc | 28.5M | -1.5x | --- |
RenovoRx Inc | 28.0M | -1.6x | --- |
Janone Inc | 30.0M | -0.6x | --- |
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.